# CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

> **NCT04603872** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 120 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphocytic Leukaemia Refractory
- Non-Hodgkin's Lymphoma, Relapsed
- Non-Hodgkin's Lymphoma Refractory

## Interventions

- **DRUG:** CD19/BCMA Targeted CAR T-cells and dasatinib
- **DRUG:** CD19/BCMA Targeted CAR T-cells

## Key facts

- **NCT ID:** NCT04603872
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-01
- **Primary completion:** 2023-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04603872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04603872, "CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04603872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*